(Q33999521)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Ina Weiner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

13 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

989-999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301208

30 December 2019

exact match

0 references

cites work

Scopolamine and Pavlovian fear conditioning in rats: dose-effect analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Context, time, and memory retrieval in the interference paradigms of Pavlovian learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Anticholinergic syndrome after anesthesia: a case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Cholinergic effects on fear conditioning I: the degraded contingency effect is disrupted by atropine but reinstated by physostigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Psychosis induced by smoking cessation clinic administered anticholinergic overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Latent inhibition in smokers vs. nonsmokers: interaction with number or intensity of preexposures?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Mesopontine neurons in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Latent inhibition: the nucleus accumbens connection revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Cholinergic systems and schizophrenia: primary pathology or epiphenomena?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Influence of the entorhinal cortex on accumbal and striatal dopaminergic responses in a latent inhibition paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The brain stem reticular formation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Construct Validity of the Animal Latent Inhibition Model of Selective Attention Deficits in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Behavioral changes after acetylcholinesterase inhibition with physostigmine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

A single administration of d-amphetamine prior to stimulus pre-exposure and conditioning attenuates latent inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The role of nicotinic and muscarinic acetylcholine receptors in attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Transient impairment of cholinergic function in the rat insular cortex disrupts the encoding of taste in conditioned taste aversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Acute scopolamine poisoning after sniffing adulterated cocaine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Reduction of latent inhibition by D-amphetamine in a conditioned suppression paradigm in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Attentional functions of cortical cholinergic inputs: What does it mean for learning and memory?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Cortical cholinergic transmission and cortical information processing in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptics in schizophrenia. Implications for a neuropharmacological model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Glucose and physostigmine effects on morphine- and amphetamine-induced increases in locomotor activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Neural substrates of latent inhibition: the switching model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The switching model of latent inhibition: an update of neural substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Disruption of latent inhibition by acute administration of low doses of amphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

The latent inhibition model of schizophrenia: further validation using the atypical neuroleptic, clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Side effects of transdermal scopolamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Effects of nicotine and amphetamine on latent inhibition in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

Differential performance of acute and chronic schizophrenics in a latent inhibition task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Acetylcholine: a neurotransmitter for learning and memory?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Transdermal scopolamine as a cause of transient psychosis in two elderly patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Clinical features of latent inhibition in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: implications for the mechanism of action of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Dose-response curves and time-course effects of selected anticholinergics on locomotor activity in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Cholinergic mechanisms in startle and prepulse inhibition: effects of the false cholinergic precursor N-aminodeanol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301208

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16971898%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

30 December 2019

0 references

1 reference